Nephrology
Conference Coverage
Novel drug slows progression of diabetic kidney disease
Finerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, significantly reduced both renal and cardiovascular events, with good...
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
Conference Coverage
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....
Conference Coverage
Survival after kidney transplantation lags in diabetes patients
Overall U.S. survival after kidney transplantation rose during 2000-2018, but less so in patients with type 1 or type 2 diabetes.
Conference Coverage
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
News
SGLT2 inhibitors have a breakout year
News
Real-world data show SGLT2 inhibitors for diabetes triple DKA risk
The findings are based on the use of three different SGLT2 inhibitors in Canada and the United Kingdom.
News
Where does dexamethasone fit in with diabetic ketoacidosis in COVID-19?
Author of new article discussing considerations around diabetic ketoacidosis in the setting of COVID-19 also speaks to the findings this week that...
Conference Coverage
Dapagliflozin’s T2D renal protection extends to ‘fast decline’ of eGFR
Another dimension of dapagliflozin’s renal protection for type 2 diabetes patients is shown in a post-hoc analysis from its cardiovascular...
News
Large COVID-19 dataset: Kidney injury in >35% of those in hospital
The clearest risk factors for the development of AKI were “the need for ventilator support or vasopressor drug treatment.”